Key statistics
On Friday, Savara Inc (YB4P:FRA) closed at 4.44, -24.75% below its 52-week high of 5.90, set on Dec 12, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.30 |
|---|---|
| High | 4.44 |
| Low | 4.30 |
| Bid | 4.44 |
| Offer | 4.52 |
| Previous close | 4.32 |
| Average volume | 128.00 |
|---|---|
| Shares outstanding | 203.47m |
| Free float | 198.86m |
| P/E (TTM) | -- |
| Market cap | 1.05bn USD |
| EPS (TTM) | -0.535 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 20:47 GMT.
More ▼
Press releases
- Savara Announces Participation in Upcoming Investor Healthcare Conferences
- Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
- Savara Announces New Employment Inducement Grant
- PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
- Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
- Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
- Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
- Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
- Savara Announces Participation in Upcoming Investor Healthcare Conferences
- Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
More ▼
